Skip to main content
Erschienen in: Zeitschrift für Rheumatologie 4/2020

17.04.2020 | Systemischer Lupus erythematodes | Leitthema

Neue Therapien beim systemischen Lupus erythematodes

verfasst von: Prof. Dr. Bimba F. Hoyer

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Ein verbessertes Verständnis der Pathomechanismen, die zur Entstehung des systemischen Lupus erythematodes (SLE) beitragen, haben in Analogie zu Erkrankungen wie der rheumatoiden Arthritis und den Spondylarthritiden auch zu neuen selektiven Therapiestrategien bei dieser entzündlichen Systemerkrankung geführt. Neue, spezifische Biologika wurden entwickelt oder sind in der Entwicklung und eröffnen neue Therapieoptionen für unsere Patienten. In diesem Zusammenhang ist v. a. Belimumab zu nennen. Der Antikörper gegen das Zytokin BAFF („B cell activating factor“)/BLyS („B lymphocyte stimulator“) ist das erste zugelassene Medikament für die Therapie des SLE in den letzten Jahrzehnten und zugleich das erste für diese Erkrankung zugelassene Biologikum. Andere Medikamente zur Behandlung von SLE-Patienten sind in der klinischen Entwicklung. Hier soll es in erster Linie um die in der Entwicklung befindlichen neuen Medikamente in der Therapie des SLE gehen.
Literatur
1.
Zurück zum Zitat Urowitz MB et al (1997) Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol 24(6):1061–1065PubMed Urowitz MB et al (1997) Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol 24(6):1061–1065PubMed
3.
Zurück zum Zitat Diaz-Lagares C et al (2012) Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 11(5):357–364PubMedCrossRef Diaz-Lagares C et al (2012) Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 11(5):357–364PubMedCrossRef
4.
Zurück zum Zitat Ezeonyeji AN, Isenberg DA (2012) Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology 51(3):476–481PubMedCrossRef Ezeonyeji AN, Isenberg DA (2012) Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology 51(3):476–481PubMedCrossRef
5.
Zurück zum Zitat Lu TY et al (2009) A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 61(4):482–487PubMedCrossRef Lu TY et al (2009) A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 61(4):482–487PubMedCrossRef
6.
Zurück zum Zitat Rovin BH et al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64(4):1215–1226PubMedCrossRef Rovin BH et al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64(4):1215–1226PubMedCrossRef
7.
Zurück zum Zitat Murray E, Perry M (2010) Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol 29(7):707–716PubMedPubMedCentralCrossRef Murray E, Perry M (2010) Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol 29(7):707–716PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Fanouriakis A et al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78(6):736–745PubMedCrossRef Fanouriakis A et al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78(6):736–745PubMedCrossRef
9.
Zurück zum Zitat Kraaij T et al (2018) The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun 91:45–54PubMedCrossRef Kraaij T et al (2018) The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun 91:45–54PubMedCrossRef
10.
Zurück zum Zitat Condon MB et al (2013) Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72(8):1280–1286PubMedCrossRef Condon MB et al (2013) Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72(8):1280–1286PubMedCrossRef
11.
Zurück zum Zitat Mysler EF et al (2013) Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 65(9):2368–2379PubMedCrossRef Mysler EF et al (2013) Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 65(9):2368–2379PubMedCrossRef
12.
Zurück zum Zitat Freeman CL, Sehn LH (2018) A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol 182(1):29–45PubMedCrossRef Freeman CL, Sehn LH (2018) A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol 182(1):29–45PubMedCrossRef
13.
Zurück zum Zitat Furie R et al (2019) A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obinutuzumab or placebo in combination with Mycophenolate Mofetil in patients with active class III or IV lupus nephritis. Arthritis Rheumatol 71:Abstract ACR Furie R et al (2019) A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obinutuzumab or placebo in combination with Mycophenolate Mofetil in patients with active class III or IV lupus nephritis. Arthritis Rheumatol 71:Abstract ACR
14.
Zurück zum Zitat Dorner T, Lipsky PE (2014) B cells: depletion or functional modulation in rheumatic diseases. Curr Opin Rheumatol 26(2):228–236PubMedCrossRef Dorner T, Lipsky PE (2014) B cells: depletion or functional modulation in rheumatic diseases. Curr Opin Rheumatol 26(2):228–236PubMedCrossRef
16.
Zurück zum Zitat Hiepe F et al (2011) Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 7(3):170–178PubMedCrossRef Hiepe F et al (2011) Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 7(3):170–178PubMedCrossRef
17.
Zurück zum Zitat Dorner T, Kinnman N, Tak PP (2010) Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther 125(3):464–475PubMedCrossRef Dorner T, Kinnman N, Tak PP (2010) Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther 125(3):464–475PubMedCrossRef
18.
Zurück zum Zitat Hoyer BF et al (2004) Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 199(11):1577–1584PubMedPubMedCentralCrossRef Hoyer BF et al (2004) Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 199(11):1577–1584PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Pena-Rossi C et al (2009) An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 18(6):547–555PubMedPubMedCentralCrossRef Pena-Rossi C et al (2009) An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 18(6):547–555PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Ginzler EM et al (2012) Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 14(1):R33PubMedPubMedCentralCrossRef Ginzler EM et al (2012) Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 14(1):R33PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Cheng Q et al (2020) Selective depletion of plasma cells in vivo based on the specificity of their secreted antibodies. Eur J Immunol 50(2):284–291PubMedCrossRef Cheng Q et al (2020) Selective depletion of plasma cells in vivo based on the specificity of their secreted antibodies. Eur J Immunol 50(2):284–291PubMedCrossRef
24.
Zurück zum Zitat Inghirami G et al (1988) Activated T lymphocytes in the peripheral blood of patients with systemic lupus erythematosus induce B cells to produce immunoglobulin. Clin Exp Rheumatol 6(3):269–276PubMed Inghirami G et al (1988) Activated T lymphocytes in the peripheral blood of patients with systemic lupus erythematosus induce B cells to produce immunoglobulin. Clin Exp Rheumatol 6(3):269–276PubMed
25.
Zurück zum Zitat Larosa M et al (2019) IL-12 and IL-23/Th17 axis in systemic lupus erythematosus. Exp Biol Med 244(1):42–51CrossRef Larosa M et al (2019) IL-12 and IL-23/Th17 axis in systemic lupus erythematosus. Exp Biol Med 244(1):42–51CrossRef
26.
Zurück zum Zitat Moreland LW et al (2002) Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46(6):1470–1479PubMedCrossRef Moreland LW et al (2002) Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46(6):1470–1479PubMedCrossRef
27.
Zurück zum Zitat Merrill JT et al (2010) The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62(10):3077–3087PubMedCrossRef Merrill JT et al (2010) The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62(10):3077–3087PubMedCrossRef
28.
Zurück zum Zitat Furie R et al (2014) Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 66(2):379–389PubMedCrossRef Furie R et al (2014) Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 66(2):379–389PubMedCrossRef
29.
Zurück zum Zitat Danion F et al (2016) Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease. Lupus 25(13):1440–1447PubMedCrossRef Danion F et al (2016) Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease. Lupus 25(13):1440–1447PubMedCrossRef
30.
Zurück zum Zitat Kalunian KC et al (2002) Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(12):3251–3258PubMedCrossRef Kalunian KC et al (2002) Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(12):3251–3258PubMedCrossRef
31.
Zurück zum Zitat Liossis SN, Sfikakis PP (2004) Costimulation blockade in the treatment of rheumatic diseases. BioDrugs 18(2):95–102PubMedCrossRef Liossis SN, Sfikakis PP (2004) Costimulation blockade in the treatment of rheumatic diseases. BioDrugs 18(2):95–102PubMedCrossRef
32.
Zurück zum Zitat Furie R et al (2019) FRI0195 efficacy and safety of dapirolizumab pegol (DZP) in patients with moderately TO severely active systemic lupus Erythematosus (SLE): a randomised, placebo (PBO)-controlled study. Ann Rheum Dis 78(Suppl 2):775–776 Furie R et al (2019) FRI0195 efficacy and safety of dapirolizumab pegol (DZP) in patients with moderately TO severely active systemic lupus Erythematosus (SLE): a randomised, placebo (PBO)-controlled study. Ann Rheum Dis 78(Suppl 2):775–776
33.
Zurück zum Zitat Humrich JY, Riemekasten G (2016) IL-2-therapy in SLE- selective reconstitution of immunological tolerance. Z Rheumatol 75(5):490–492PubMedCrossRef Humrich JY, Riemekasten G (2016) IL-2-therapy in SLE- selective reconstitution of immunological tolerance. Z Rheumatol 75(5):490–492PubMedCrossRef
34.
Zurück zum Zitat Humrich J et al (2019) Low-dose interleukin‑2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. Lancet Rheumatol 1(1):E44–E54CrossRef Humrich J et al (2019) Low-dose interleukin‑2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. Lancet Rheumatol 1(1):E44–E54CrossRef
35.
Zurück zum Zitat Huang X et al (2007) Dysregulated expression of interleukin-23 and interleukin-12 subunits in systemic lupus erythematosus patients. Mod Rheumatol 17(3):220–223PubMedCrossRef Huang X et al (2007) Dysregulated expression of interleukin-23 and interleukin-12 subunits in systemic lupus erythematosus patients. Mod Rheumatol 17(3):220–223PubMedCrossRef
36.
Zurück zum Zitat Ball EM et al (2014) Plasma IL‑6 levels correlate with clinical and ultrasound measures of arthritis in patients with systemic lupus erythematosus. Lupus 23(1):46–56PubMedCrossRef Ball EM et al (2014) Plasma IL‑6 levels correlate with clinical and ultrasound measures of arthritis in patients with systemic lupus erythematosus. Lupus 23(1):46–56PubMedCrossRef
37.
Zurück zum Zitat Ripley BJ et al (2005) Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann Rheum Dis 64(6):849–853PubMedPubMedCentralCrossRef Ripley BJ et al (2005) Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann Rheum Dis 64(6):849–853PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Tsai CY et al (2000) Increased excretions of beta2-microglobulin, IL‑6, and IL‑8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 85(3):207–214PubMedCrossRef Tsai CY et al (2000) Increased excretions of beta2-microglobulin, IL‑6, and IL‑8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 85(3):207–214PubMedCrossRef
39.
Zurück zum Zitat Illei GG et al (2010) Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62(2):542–552PubMedPubMedCentralCrossRef Illei GG et al (2010) Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62(2):542–552PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Shirota Y et al (2013) Impact of anti-interleukin‑6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis 72(1):118–128PubMedCrossRef Shirota Y et al (2013) Impact of anti-interleukin‑6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis 72(1):118–128PubMedCrossRef
41.
Zurück zum Zitat Rovin BH, Vollenhoven RF van, Aranow C, Wagner C, Gordon R, Zhuang Y et al (2016) A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis Rheumatol 68(9):2174–2183. https://doi.org/10.1002/art.39722 CrossRefPubMedPubMedCentral Rovin BH, Vollenhoven RF van, Aranow C, Wagner C, Gordon R, Zhuang Y et al (2016) A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis Rheumatol 68(9):2174–2183. https://​doi.​org/​10.​1002/​art.​39722 CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Rose T et al (2013) IFNalpha and its response proteins, IP-10 and SIGLEC‑1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis 72(10):1639–1645PubMedCrossRef Rose T et al (2013) IFNalpha and its response proteins, IP-10 and SIGLEC‑1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis 72(10):1639–1645PubMedCrossRef
43.
Zurück zum Zitat McBride JM et al (2012) Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 64(11):3666–3676PubMedCrossRef McBride JM et al (2012) Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 64(11):3666–3676PubMedCrossRef
44.
Zurück zum Zitat Petri M et al (2013) Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 65(4):1011–1021PubMedPubMedCentralCrossRef Petri M et al (2013) Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 65(4):1011–1021PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Morand EF et al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382(3):211–221PubMedCrossRef Morand EF et al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382(3):211–221PubMedCrossRef
46.
Zurück zum Zitat Werth VP, Merrill JT (2019) A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus. Br J Dermatol 180(5):964–965PubMedPubMedCentralCrossRef Werth VP, Merrill JT (2019) A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus. Br J Dermatol 180(5):964–965PubMedPubMedCentralCrossRef
Metadaten
Titel
Neue Therapien beim systemischen Lupus erythematodes
verfasst von
Prof. Dr. Bimba F. Hoyer
Publikationsdatum
17.04.2020
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe 4/2020
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-020-00788-1

Weitere Artikel der Ausgabe 4/2020

Zeitschrift für Rheumatologie 4/2020 Zur Ausgabe

Mitteilungen der DGRh

Mitteilungen der DGRh

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.